Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Alzheimer's disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDs). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDs cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.

[1]  B. Jenkins,et al.  Anti-inflammatory treatment in AD mice protects against neuronal pathology , 2010, Experimental Neurology.

[2]  B. Hyman,et al.  Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease , 2010, Neurobiology of Disease.

[3]  Winnie S. Liang,et al.  Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology , 2010, Neurobiology of Aging.

[4]  D. Dickson,et al.  Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[6]  K. Herrup,et al.  NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. , 2009, The Journal of clinical investigation.

[7]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[8]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[9]  G. Arendash,et al.  Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease , 2009, Glia.

[10]  G. Cole,et al.  Omega-3 fatty acids and dementia. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  H. Braak,et al.  Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.

[12]  S. Haneuse,et al.  Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort , 2009, Neurology.

[13]  J. Palmblad,et al.  Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study , 2009, Dementia and Geriatric Cognitive Disorders.

[14]  P. Pasqualetti,et al.  A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease , 2009, Aging clinical and experimental research.

[15]  L. Lue,et al.  Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation , 2009, Experimental Neurology.

[16]  A. Luster,et al.  Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.

[17]  G. Small,et al.  Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  F. LaFerla,et al.  Blocking Aβ42 Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between Aβ and Tau Pathology , 2008, The Journal of Neuroscience.

[19]  Edward E Knaus,et al.  Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. , 2008, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[20]  R. Green,et al.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. , 2008, Archives of neurology.

[21]  Takashi Morihara,et al.  Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[22]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[23]  P. Zandi,et al.  No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies , 2008, Neurology.

[24]  D. Bennett,et al.  Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology , 2008, Neurology.

[25]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[26]  H. Brodaty,et al.  Faculty Opinions recommendation of NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. , 2008 .

[27]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[28]  P. Zandi,et al.  Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: The Cache County Study , 2008, Alzheimer's & Dementia.

[29]  B. Jenkins,et al.  Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice , 2008, Brain Research.

[30]  R. Veerhuis,et al.  Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. , 2008, Current pharmaceutical design.

[31]  R. A. Wallis,et al.  Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. , 2008, Brain : a journal of neurology.

[32]  L. Thal,et al.  Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. , 2008, Current Alzheimer research.

[33]  T. Rea,et al.  NSAID use and dementia risk in the Cardiovascular Health Study* , 2008, Neurology.

[34]  J. Ferro,et al.  A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment: The TRIMCI Study , 2008, Alzheimer disease and associated disorders.

[35]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[36]  T. Golde,et al.  Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice , 2007, BMC Neuroscience.

[37]  P. Zandi,et al.  Does NSAID use modify cognitive trajectories in the elderly? , 2007, Neurology.

[38]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[39]  F. Schmitt,et al.  Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment , 2007, Neurology.

[40]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[41]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[42]  Michal Schwartz,et al.  Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Wuu,et al.  Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment , 2006, Journal of neuropathology and experimental neurology.

[44]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[45]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[46]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[47]  C. Aoki,et al.  Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses , 2005, The Journal of comparative neurology.

[48]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[49]  R. Green,et al.  Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study , 2005, BMC geriatrics.

[50]  T. Lanz,et al.  Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures , 2005, Journal of Pharmacology and Experimental Therapeutics.

[51]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[52]  G. Cole,et al.  The microglial phagocytic role with specific plaque types in the Alzheimer disease brain , 2004, Neurobiology of Aging.

[53]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[54]  P. Dash,et al.  Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats , 2003, Brain Research.

[55]  T. Montine,et al.  Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease , 2003, Journal of Neuroimmunology.

[56]  R. Motter,et al.  Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[58]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[59]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[60]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[61]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[62]  J. Overmier,et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.

[63]  M. Staufenbiel,et al.  3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid , 2001, Neurobiology of Aging.

[64]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[65]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[66]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[67]  G. Pasinetti,et al.  Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. , 1999, The American journal of pathology.

[68]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[69]  A. Hoes,et al.  NSAIDs and incident Alzheimer’s disease. the Rotterdam study , 1998, Neurobiology of Aging.

[70]  E. Masliah,et al.  Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype , 1998, Journal of Neuroimmunology.

[71]  D. Munoz,et al.  Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging , 1998, Neurology.

[72]  N. Bazan,et al.  Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic alzheimer neocortex , 1997, Journal of neuroscience research.

[73]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[74]  G. Cole,et al.  Rodent models of Alzheimer's disease: Rat aβ infusion approaches to amyloid deposits , 1996, Neurobiology of Aging.

[75]  D. Lahiri,et al.  Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. , 1995, Brain research. Molecular brain research.

[76]  M. Pericak-Vance,et al.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.

[77]  B. Hyman,et al.  Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. , 1995, Archives of neurology.

[78]  G. Heinrich.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. , 1989, The New England journal of medicine.

[79]  S. Angaji,et al.  Neuroprotective Effects Of Curcumin , 2011 .

[80]  P. Aisen.  The inflammatory hypothesis of Alzheimer disease: dead or alive? , 2008, Alzheimer disease and associated disorders.

[81]  Gerald Rimbach,et al.  Impact of apoE genotype on oxidative stress, inflammation and disease risk. , 2008, Molecular nutrition & food research.

[82]  B. Teter,et al.  Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. , 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[83]  Michael T Heneka,et al.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. , 2005, Brain : a journal of neurology.

[84]  T. Montine,et al.  Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. , 2005, Brain pathology.

[85]  Y. Surh,et al.  Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. , 2005, Free radical biology & medicine.

[86]  Khadija Iqbal,et al.  Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils , 2004, Acta Neuropathologica.

[87]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[88]  Michael T Heneka,et al.  Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[89]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[90]  H. Soininen,et al.  Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. , 2000, Journal of Alzheimer's disease : JAD.

[91]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[92]  T. Shirao,et al.  Disappearance of actin‐binding protein, drebrin, from hippocampal synapses in alzheimer's disease , 1996, Journal of neuroscience research.

[93]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .